Synthesis, characterization, and imaging of radiopaque bismuth beads for image-guided transarterial embolization

Ayele H. Negussie, Quirina M. B. de Ruiter, Hugh Britton, Danielle Donahue, Quentin Boffi, Young-Seung Kim, William F. Pritchard, Chrit Moonen, Gert Storm, Andrew L. Lewis, Bradford J. WoodScientific 2021 · DOI

Abstract

Current therapy for hypervascular cancers, such as hepatocellular carcinoma, involves the occlusion of tumor blood supply via the arterial infusion of embolic microspheres (beads). These beads are typically suspended in iodine-based contrast agents and delivered under fluoroscopic guidance. However, existing radiopaque beads also utilize iodine as a radiopacifier, making them indistinguishable from the surrounding liquid contrast on post-procedure imaging. This study describes the synthesis and characterization of novel imageable beads using bismuth as a radiopacifier. By leveraging the unique binding energy of bismuth's k-shell electrons (k-edge), these beads can be distinguished from iodine-based contrast using clinical dual-energy computed tomography (CT). The synthesized bismuth beads were spherical, compatible with clinical microcatheters, and demonstrated uniform bismuth distribution. This technology may enhance diagnostic follow-up by allowing clinicians to separate the embolic bead distribution from residual contrast, potentially enabling dual-drug tracking and more precise treatment monitoring.

Introduction

In interventional oncology, transarterial embolization is a cornerstone treatment for hypervascular tumors. Physicians inject embolic microspheres into the arteries feeding a tumor to block blood flow and, in many cases, deliver localized chemotherapy. To visualize this process in real-time, liquid iodine-based contrast agents are used.

A significant clinical challenge arises during post-procedural follow-up. Because current "imageable" beads also rely on iodine for radiopacity, they appear identical to the liquid contrast on CT scans. This ambiguity makes it difficult to determine if the drug-loaded beads reached the intended target or if the observed radiopacity is merely lingering contrast. To solve this, researchers have turned to bismuth ($Z=83$), an element with a significantly higher k-edge (90.5 keV) than iodine (33.2 keV), allowing for material-specific identification through advanced imaging techniques.

Materials and Methods

The research team developed a chemical synthesis route to covalently attach bismuth to the polymer backbone of polyvinyl alcohol (PVA) microspheres. The process involved modifying the beads with a bifunctional linker to incorporate a DOTA-like chelating macrocycle.

Synthesis scheme for bismuth-loaded embolic beads (6 and 7) from the starting PVA-based macrocycle (1).

Two primary synthesis routes were evaluated to optimize the distribution of the radiopacifier:

  1. Aqueous Chelation (Bead 6): This method resulted in a uniform distribution of bismuth throughout the entire volume of the bead.
  2. Organic Solvent Chelation (Bead 7): This route tended to concentrate the bismuth on the outer shell of the microsphere.

The physical properties of the beads, including size (100–160 µm) and spherical morphology, were confirmed via Scanning Electron Microscopy (SEM) and Energy-Dispersive X-ray (EDX) analysis.

Imaging Physics and Dual-Energy CT

The core innovation of this study is the application of Dual-Energy CT (DECT) to distinguish between materials. DECT captures images at two different X-ray energy levels (e.g., 80 kVp and 150 kVp). Because bismuth and iodine absorb these energies differently due to their distinct k-edges, a mathematical Dual Energy Index (DEI) can be calculated for each voxel in the scan. By setting a specific DEI threshold, the imaging software can "decompose" the materials, effectively color-coding the bismuth beads separately from the iodine contrast.

Results

Radiopacity and Separation

The bismuth beads demonstrated high radiopacity, reaching approximately 5200 Hounsfield Units (HU), which exceeds the performance of current clinical iodinated beads (~4700 HU). In phantom studies using agarose gels, the researchers achieved near-perfect material separation using a DEI threshold of 0.06. Under these conditions, 99.9% of iodine voxels were correctly identified, while 99.7% of bismuth voxels were successfully excluded from the iodine signal.

Clinical Compatibility

To ensure the beads are practical for real-world use, they were tested for delivery through standard clinical 2.0 Fr and 2.4 Fr microcatheters. The beads remained robust and did not cause clogging, indicating they possess the mechanical integrity required for transarterial procedures.

Discussion and Future Directions

While these results are promising, several steps remain before clinical adoption. The current study utilized static in vitro phantoms; future work must evaluate performance in the dynamic environment of a living liver, where blood flow and motion may complicate DECT algorithms. Additionally, while the beads are chemically similar to existing drug-eluting platforms, specific studies on the loading and release kinetics of chemotherapy drugs like doxorubicin are needed.

Ultimately, the ability to spatially distinguish two different radiopaque markers opens the door for "multiplexed" embolization. Clinicians could potentially use iodine-based beads for one drug and bismuth-based beads for another, tracking the delivery of a dual-drug regimen in a single non-invasive scan.

Summary updated

Abstract

Current therapy for hypervascular cancers, e.g., hepatocellular carcinoma, includes occlusion of the tumor blood supply by arterial infusion of embolic microspheres (beads) suspended in iodine-based contrast under fluoroscopic guidance. Available radiopaque, imageable beads use iodine as the radiopacifier and cannot be differentiated from contrast. This study aimed to synthesize and characterize imageable beads using bismuth as the radiopacifier that could be distinguished from iodine contrast based upon the difference in the binding energy of k-shell electrons (k-edge). Radiodense bismuth beads were successfully synthesized some with uniform bismuth distribution across the beads. The beads were spherical and could be infused through clinical microcatheters. The bismuth beads could be imaged with clinical dual-energy computed tomography (CT), where iodine-based contrast could be distinguished from the microspheres. The ability to separate iodine from bismuth may enhance the diagnostic information acquired on follow-up CT, identifying the distribution of the embolic beads separately from the contrast. Furthermore, with sequential use of iodine- and bismuth-based beads, the two radiopaque beads could be spatially distinguished on imaging, which may enable the development of dual drug delivery and dual tracking.
BibTeX
@inproceedings{negussie2021synthesis,
  author = {Ayele H. Negussie and Quirina M. B. de Ruiter and Hugh Britton and Danielle Donahue and Quentin Boffi and Young-Seung Kim and William F. Pritchard and Chrit Moonen and Gert Storm and Andrew L. Lewis and Bradford J. Wood},
  title = {{Synthesis, characterization, and imaging of radiopaque bismuth beads for image-guided transarterial embolization}},
  booktitle = {Scientific},
  year = {2021},
  doi = {10.1038/s41598-020-79900-z},
}
Figure